The announcement of positive safety and efficacy data for VYN201 from a Phase 1b trial is likely to be viewed positively by investors and could lead to increased investor confidence in VYNE Therapeutics' product pipeline. This, in turn, could have a positive short-term impact on the company's stock price as it demonstrates progress in developing treatments with potential market demand.